Netherlands
Every company in the roster headquartered in Netherlands.
Every company in the roster headquartered in Netherlands.
7 of 7 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
NewAmsterdam PharmaNAMS · Nasdaq | 2 assets: 2 Ph 3 | ObicetrapibPhase 3 · Type 2 DiabetesPartial signal | Nov 2026Obicetrapib · Phase 3 | $2.3B | $628MSep 2026 | ~16.7 qtrs | $158M |
uniQureQURE · Nasdaq | 3 assets: 1 approved, 2 Ph 2 | AMT-260Phase 1/2 · Epilepsy | 30 Nov 2026AMT-260 · Phase 1/2 | $1.3B | $670MSep 2026 | ~13.9 qtrs | $133M |
argenxARGX · Nasdaq | 2 assets: 2 approved | Approved assets only | None on record | — | $702MDec 2023 | — | — |
AmyriAD Therapeutics B.V.Private | 1 asset: 1 Ph 2 | Inidascamine (RL-007)Phase 2 · Cognitive Impairment Associated with Schizophrenia | None on record | — | — | — | — |
Avanzanite BiosciencePrivate | 1 asset: 1 approved | Approved assets only | Mar 2029Mitapivat · Phase 3 | — | — | — | — |
Nordic Group B.V.Private | 1 asset: 1 Ph 3 | S-1Phase 3 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
Sairopa B.V.Private | 1 asset: 1 Ph 1 | ADU-1805Phase 1 · Non-Small Cell Lung Cancer | May 2027ADU-1805 · Phase 1 | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.